Pharmacokinetics of Tricaprilin Including Food Effect on Ketone Body Production

NCT ID: NCT03551769

Last Updated: 2019-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-05

Study Completion Date

2018-08-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase I, single center, open label, fixed-order, crossover, food-effect, pharmacokinetic (PK) study recruiting healthy, adult, male subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1, Period 1

Study drug administered concurrently with a standard meal

Group Type EXPERIMENTAL

tricaprilin

Intervention Type DRUG

Tricaprilin formulated as AC-SD-01

standard meal

Intervention Type OTHER

standard meal

Cohort 1, Period 2

Study drug administered 30 minutes after a standard meal

Group Type EXPERIMENTAL

tricaprilin

Intervention Type DRUG

Tricaprilin formulated as AC-SD-01

standard meal

Intervention Type OTHER

standard meal

Cohort 1, Period 3

Study drug administered 30 minutes after a high-fat meal

Group Type EXPERIMENTAL

tricaprilin

Intervention Type DRUG

Tricaprilin formulated as AC-SD-01

high-fat meal

Intervention Type OTHER

high-fat meal

Cohort 1, Period 4

Study drug administered after an overnight fast

Group Type EXPERIMENTAL

tricaprilin

Intervention Type DRUG

Tricaprilin formulated as AC-SD-01

Cohort 2, Period 1

Study drug administered 30 minutes after a standard meal (Asian)

Group Type EXPERIMENTAL

tricaprilin

Intervention Type DRUG

Tricaprilin formulated as AC-SD-01

standard meal

Intervention Type OTHER

standard meal

Cohort 2, Period 2

Study drug administered after an overnight fast (Asian)

Group Type EXPERIMENTAL

tricaprilin

Intervention Type DRUG

Tricaprilin formulated as AC-SD-01

overnight fast

Intervention Type OTHER

fasting for at least 9 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tricaprilin

Tricaprilin formulated as AC-SD-01

Intervention Type DRUG

standard meal

standard meal

Intervention Type OTHER

high-fat meal

high-fat meal

Intervention Type OTHER

overnight fast

fasting for at least 9 hours

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adult male, ages 18 - 55
* Able to consume a regular diet and one high fat meal; no specific dietary requirements
* Cohort 2 (Asian subject population) restricted to being of Japanese or Chinese heritage

Exclusion Criteria

* Presence of any illness or condition that, in the opinion of the investigator might confound the study results or poses risk to the subject
* Has been on a ketogenic diet as supported by review of a food diary
* Has positive Urine Drug Screen or alcohol results at Screening
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cerecin

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nucleus Network

Melbourne, Victoria, Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AC-18-016_FE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of TAK-227 in Healthy Adults
NCT05818956 COMPLETED PHASE1